← Leaderboards
Lynn E Heasley
University Of Colorado Denver
$6,919,747
Attributed
$6,919,747
Total exposure
10
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $570.2K · FY2007–25$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,919,747 · 8
VA$0 · 2
By mechanism
R01$4,866,492 · 4
P50$1,614,899 · 3
P01$438,356 · 1
I01$0 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Sharon R. Pine$4,344,969
- Tatiana G Kutateladze$17,515,896
- Raphael A. Nemenoff$15,000,654
- Mary Elaine Reyland$13,618,689
- Kirsten H Limesand$6,799,601
Others in their field
Top investigators on “Pathway Interactions”
- David Heimbrook · Leidos Biomedical Research, Inc.$202,777,247
- Ralph Parchment · Leidos Biomedical Research, Inc.$146,974,543
- David R. Weir · University Of Michigan At Ann Arbor$129,316,139
- Daniel Ernest Ford · Johns Hopkins University$108,075,637
- David W Simpson · University Of Southern California$88,046,235
- Charles D. Blanke · Oregon Health And Science University$86,571,896
Research focus
Pathway InteractionsTumorEpidermal Growth Factor ReceptorCell LineSignal TransductionResponseNeoplastic CellTyrosine Kinase InhibitorReceptor Protein-Tyrosine KinasesIn VivoGrowthInhibitor/AntagonistMutantTherapeutic TargetMitogen Activated Protein KinaseMalignant Neoplasm Of LungBaseMessenger RnaOncogenesArchivesCancer CellExhibitsOncogenicMalignant Neoplasms
Grant awards (45)
Colorado HNC SPORE Developmental Research Program$101,123
P50 · FY2025 · CA · contact PI
Role of Adaptive Immunity in Lung Cancer Response to Oncogene-targeted Therapeutics$0
I01 · FY2025 · VA · contact PI
Role of Adaptive Immunity in Lung Cancer Response to Oncogene-targeted Therapeutics$0
I01 · FY2024 · VA · contact PI
Regulation of Targeted Therapeutic Response by the Immune Microenvironment in HNSCC$0
I01 · FY2022 · VA · contact PI
Colorado HNC SPORE Career Enhancement Program$97,962
P50 · FY2021 · CA · contact PI
Regulation of Targeted Therapeutic Response by the Immune Microenvironment in HNSCC$0
I01 · FY2021 · VA · contact PI
Regulation of Targeted Therapeutic Response by the Immune Microenvironment in HNSCC$0
I01 · FY2020 · VA · contact PI
Regulation of Targeted Therapeutic Response by the Immune Microenvironment in HNSCC$0
I01 · FY2019 · VA · contact PI
Targeting FGFR1 Signaling in Lung Cancer$290,198
P50 · FY2018 · CA · contact PI
Targeting FGFR1 Signaling in Lung Cancer$6,134
P50 · FY2018 · CA · contact PI
Targeting FGFR1 Signaling in Lung Cancer$295,042
P50 · FY2017 · CA · contact PI
An FGFR1 oncogene driver pathway in head and neck cancer$0
I01 · FY2017 · VA · contact PI
Targeting FGFR1 Signaling in Lung Cancer$273,097
P50 · FY2016 · CA · contact PI
An FGFR1 oncogene driver pathway in head and neck cancer$0
I01 · FY2016 · VA · contact PI
Targeting FGFR1 Signaling in Lung Cancer$276,437
P50 · FY2015 · CA · contact PI
An FGFR1 oncogene driver pathway in head and neck cancer$0
I01 · FY2015 · VA · contact PI
Targeting FGFR1 Signaling in Lung Cancer$274,906
P50 · FY2014 · CA · contact PI
An FGFR1 oncogene driver pathway in head and neck cancer$0
I01 · FY2014 · VA · contact PI
FGF-2 Autocrine Signaling in Lung Cancer$303,684
R01 · FY2012 · CA · contact PI
FGF-2 Autocrine Signaling in Lung Cancer$303,684
R01 · FY2011 · CA · contact PI
Role of JNK Pathway in Lung Tumorigenesis$247,478
R01 · FY2011 · CA · contact PI
FGF-2 Autocrine Signaling in Lung Cancer$313,657
R01 · FY2010 · CA · contact PI
Role of JNK Pathway in Lung Tumorigenesis$255,132
R01 · FY2010 · CA · contact PI
FGF-2 Autocrine Signaling in Lung Cancer$314,653
R01 · FY2009 · CA · contact PI
Role of JNK Pathway in Lung Tumorigenesis$255,132
R01 · FY2009 · CA · contact PI
FGF-2 Autocrine Signaling in Lung Cancer$315,068
R01 · FY2008 · CA · contact PI
Role of JNK Pathway in Lung Tumorigenesis$255,132
R01 · FY2008 · CA · contact PI
Role of JNK Pathway in Lung Tumorigenesis$255,132
R01 · FY2007 · CA · contact PI
MAP KINASES AS MEDIATORS OF DIABETIC NEUROPATHY$260,820
R01 · FY2004 · DK
Integrated MAP Kinase Signaling In Cell Differentiation$185,910
R01 · FY2004 · GM
MAP KINASES AS MEDIATORS OF DIABETIC NEUROPATHY$260,820
R01 · FY2003 · DK
Integrated MAP Kinase Signaling In Cell Differentiation$185,910
R01 · FY2003 · GM
MAP KINASES AS MEDIATORS OF DIABETIC NEUROPATHY$260,820
R01 · FY2002 · DK
Integrated MAP Kinase Signaling In Cell Differentiation$185,910
R01 · FY2002 · GM
VASOPRESSIN SIGNAL TRANSDUCTION IN SMALL CELL LUNG CANCER$0
P01 · FY2002 · DK
VASOPRESSIN SIGNAL TRANSDUCTION IN SMALL CELL LUNG CANCER$0
P01 · FY2002 · DK
VASOPRESSIN SIGNAL TRANSDUCTION IN SMALL CELL LUNG CANCER$0
P01 · FY2002 · DK
MAP KINASES AS MEDIATORS OF DIABETIC NEUROPATHY$260,820
R01 · FY2001 · DK
Integrated MAP Kinase Signaling In Cell Differentiation$185,910
R01 · FY2001 · GM
VASOPRESSIN SIGNAL TRANSDUCTION IN SMALL CELL LUNG CANCER$0
P01 · FY2001 · DK
VASOPRESSIN SIGNAL TRANSDUCTION IN SMALL CELL LUNG CANCER$0
P01 · FY2001 · DK
MAP KINASES AS MEDIATORS OF DIABETIC NEUROPATHY$260,820
R01 · FY2000 · DK
VASOPRESSIN SIGNAL TRANSDUCTION IN SMALL CELL LUNG CANCER$219,178
P01 · FY2000 · DK
VASOPRESSIN SIGNAL TRANSDUCTION IN SMALL CELL LUNG CANCER$219,178
P01 · FY2000 · DK
VASOPRESSIN SIGNAL TRANSDUCTION IN SMALL CELL LUNG CANCER$0
P01 · FY2000 · DK